ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
NexGel Inc

NexGel Inc (NXGL)

3.59
0.03
(0.84%)
Closed December 04 4:00PM
3.64
0.05
( 1.39% )
Pre Market: 8:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
3.64
Bid
3.54
Ask
3.64
Volume
300
0.00 Day's Range 0.00
1.84 52 Week Range 3.85
Market Cap
Previous Close
3.59
Open
-
Last Trade Time
08:00:02
Financial Volume
-
VWAP
-
Average Volume (3m)
68,439
Shares Outstanding
6,790,777
Dividend Yield
-
PE Ratio
-7.72
Earnings Per Share (EPS)
-0.46
Revenue
4.09M
Net Profit
-3.16M

About NexGel Inc

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels an... NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. The company recognizes revenue from contract manufacturing. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
NexGel Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NXGL. The last closing price for NexGel was $3.59. Over the last year, NexGel shares have traded in a share price range of $ 1.84 to $ 3.85.

NexGel currently has 6,790,777 shares outstanding. The market capitalization of NexGel is $24.38 million. NexGel has a price to earnings ratio (PE ratio) of -7.72.

NXGL Latest News

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, 2024

LANGHORNE, Pa., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially

Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing Gross profit margin for the quarter was 43.6% compared to 28.2% in...

NEXGEL Announces $2,000,000 Registered Direct Offering

LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL to Report Third Quarter 2024 Financial Results on November 13th

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading...

NEXGEL to Participate in Upcoming October Investor Conferences

LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL Preannounces Expected Record Third Quarter 2024 Revenue of $2.85 Million, an Increase of Approximately 133% Year-Over-Year and 98% Sequentially

LANGHORNE, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...

NEXGEL's Beauty Brand, Silly George, Partners with Multi-Talented Artist and Entrepreneur, James Maslow, to Promote Innovative Eyelash Collection

LANGHORNE, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), leading provider of medical and over-the-counter (OTC) products including...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.298.656716417913.353.853.18960573.49270018CS
40.828.16901408452.843.852.761023013.31595758CS
120.8831.8840579712.763.852.4684393.07540945CS
261.5876.69902912622.063.851.84567212.91104547CS
521.4767.74193548392.173.851.84379222.79253733CS
156-0.76-17.27272727274.44.661.09715822.59086476CS
260-0.76-17.27272727274.44.661.09715822.59086476CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RKDAArcadia Biosciences Inc
$ 7.25
(168.82%)
10.13M
PRFXPainReform Ltd
$ 5.20
(94.03%)
16.39M
BJDXBluejay Diagnostics Inc
$ 6.63
(70.44%)
11.82M
TARAProtara Therapeutics Inc
$ 5.92
(67.23%)
22.35M
SVMHSRIVARU Holding Ltd
$ 0.035
(48.94%)
276.29M
SRMSRM Entertainment Inc
$ 0.70
(-39.66%)
1.76M
EEIQEpicQuest Education Group International Ltd
$ 0.698
(-33.52%)
70.92k
STECSantech Holdings Limited
$ 0.6822
(-29.67%)
4.08M
CYCNCyclerion Therapeutics Inc
$ 4.47
(-29.61%)
357.03k
BLUEbluebird bio Inc
$ 0.5254
(-28.64%)
1.8M
SVMHSRIVARU Holding Ltd
$ 0.0352
(49.79%)
276.37M
TARAProtara Therapeutics Inc
$ 5.92
(67.23%)
22.36M
PRFXPainReform Ltd
$ 5.1802
(93.29%)
16.4M
PBMPsyence Biomedical Ltd
$ 3.25
(28.97%)
13.87M
BJDXBluejay Diagnostics Inc
$ 6.60
(69.67%)
11.82M

NXGL Discussion

View Posts
TrendTrade2016 TrendTrade2016 3 weeks ago
NXGL...MY NEXT BIO BEAST READY TO ROAR THROUGH WALL STREET
👍️0
Monksdream Monksdream 4 weeks ago
NXGL, new 52 week high
👍️0
81vette 81vette 2 months ago
Looks like flipping the warrents would have been good last few days
👍️0
Helter Skelter Helter Skelter 2 months ago
Expecting earnings report around Nov 14th...🤪
👍️0
Helter Skelter Helter Skelter 2 months ago
Hey 81vette, expecting earnings' NEWS any moment/day.
Also anticipating a PROFIT which should send $NXGL, I'm thinking...😺
👍️0
81vette 81vette 2 months ago
Hey bro,good to see you,yes it’s been stairstepping up nicely since early 2023
Thanks for reminding me about it!!
👍️0
Helter Skelter Helter Skelter 2 months ago
Looking for 100% gain from here (2.80) when earnings are released around Nov. 14, 2024.

As of August 13, 2024, the registrant had 6,324,266 shares of common stock outstanding.



$NXGL



👉️ NXGL 10Q Period Ending June 30, 2024
👍️0
Monksdream Monksdream 6 months ago
NXGL under $3
👍️0
tdag910 tdag910 9 months ago
Winner winner chicken dinner!!
👍️0
Pinksatthehotel Pinksatthehotel 9 months ago
Looking good!
👍️0
tdag910 tdag910 1 year ago
Anybody home?
👍️0
alyck alyck 2 years ago
NXGL looking great! Solidly over $2 and volume increasing. Keep it going
👍️0
81vette 81vette 2 years ago
Ended @New 52 week high,blue sky babe!! Enjoy the weekend everyone!!
👍️0
81vette 81vette 2 years ago
contracts with pro sports teams will make brand huge,building a great company,investment in packaging plant was wise
👍️0
81vette 81vette 2 years ago
For the first quarter of 2023, revenue totaled $620 thousand and increased by $224 thousand, or 56.6%, compared to $396 thousand for the same period the year prior. The increase in overall revenues was primarily due to sales growth in both contract manufacturing and branded products. Revenue during the first quarter of 2023 includes one full month of revenue contribution from the Company’s newly formed joint venture with C.G. Laboratories.first quarter we delivered 56.6% revenue growth year-over-year, driven by increased sales in contract manufacturing and branded consumer products. We also started to see contribution in March from our new joint venture with CG Labs. During the quarter, we launched several new products and invested strategically in sales and marketing to support those launches. We are already starting to see the financial returns from these investments in the second quarter, as well as from our new JV.” “Based on the dynamic changes to our business, which include the March 1 joint venture, I feel it’s important to provide a one-time exception to our policy of not providing guidance. Based on these developments and our progress to date, we are projecting $1.0 million in revenue for the second quarter of 2023, an increase of 78.2% year-over-year. Complementing this, we had approximately $5.8 million in cash and cash equivalents at quarter-end, which gives us sufficient runway to operate and the ability to be opportunistic about further potential investments to accelerate our growth.”Acquired a 50% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC, with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business.
Executed a supply agreement with a large new customer relating to a new consumer product.Launched advertising and marketing initiative, which has increased branded product sales.
👍️ 1
81vette 81vette 2 years ago
watch demand,next move up thru 52 week high,very low supply atm
👍️0
81vette 81vette 2 years ago
GOLDEN CROSS is best indicator of long bulls,follow the money is the saying
👍️0
81vette 81vette 2 years ago
eps q/q up 60%,is why moving up,big profit coming,great future $ deals,expect institutions loading long,way undervalued@ 10M mkt cap
👍️0
81vette 81vette 2 years ago
GOLDEN CROSS now,thru triple top res.,52week high>$2.00,then blue sky
👍️0
81vette 81vette 2 years ago
4M float,5M o/s,.52%short,buy vol 15X ave,not optionable,shares borrow ava. dropped 400% with pre-mkt volume,easily could go ZERO BORROW with this low float/os
👍️0

Your Recent History

Delayed Upgrade Clock